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Whilst prognosis has improved dramatically over recent years for
some childhood leukaemias, this is not the case for adult acute
myeloid leukaemia (AML). Patients with AML are treated with a
combination regimen containing an anthracycline teamed with
cytosine arabinoside (ara-C). Initial remission rates are typically
around 70% (Åström et al, 2000), however patients tend to relapse
early and less than 25% can expect to have a sustained, long-term
survival. Drug resistance remains one of the major factors leading
to treatment failure. Multidrug resistance (MDR) associated with
overexpression of P-glycoprotein is prevalent in haematological
malignancies. Whilst some MDR modulation regimens have
shown promise, generally early results have been disappointing
(Covelli, 1999). 
Interestingly, whilst the in vitro anthracycline sensitivity of blast
cells from patients with AML predicts initial response to therapy
(Sargent et al, 1997), a recent study suggests that it is in vitro res-
istance to the antimetabolite ara-C that correlates with early
relapse (Klumper et al, 1996). Resistance to ara-C can be attri-
buted to many factors but alterations in phosphorylation of ara-C
to its active metabolite ara-CTP has been widely believed to be the
rate-limiting step leading to the incorporation of ara-CTP into
DNA with subsequent induction of DNA strand breaks (Freund 
et al, 1998). This is thought to cause termination of chain elonga-
tion and switch on apoptosis by a mechanism not yet fully under-
stood. Circumvention of resistance to ara-C has therefore centred
on compounds which can increase conversion to the active
metabolite by directly increasing cellular phosphorylation e.g.
bryostatin (Elgie et al, 1998) or fludarabine by increasing deoxy-
cytidine kinase activity (Plunkett and Gandhi, 1993). 
A novel approach to the problem of drug resistance in AML
would be to exploit the fact that drug-resistant cells often have an
increased capacity to repair DNA damage caused by cytotoxic
attack (Barret and Hill, 1998). By attacking a resistance mech-
anism common to many different classes of cytotoxic agent rather
than using resistance modulators to intervene in specific pathways,
we hoped to address the issue of pleiotropic drug resistance. We
have previously shown that it is possible to inhibit repair of
DNA/platinum adducts using the DNA polymerase inhibitor
aphidicolin in cells from patients with ovarian cancer (Sargent 
et al, 1996). Moreover, we found that aphidicolin had a 
greater effect in cells found resistant in vitro to the platinum
agents. 
Aphidicolin glycinate, the water-soluble analogue of aphid-
icolin entered Phase I trials and results showed that whilst 
toxicity was limited, there did not appear to be significant anti-
tumour effect when given as a single agent (Sessa et al, 1991).
Preclinical studies suggested this compound may be effective
when combined with a platinum agent but the clinical studies were
not completed and the true worth of this compound has never been
determined. 
In this report, we have investigated the use of aphidicolin to
modulate resistance to the DNA damaging agents commonly used
to treat AML. Results of a pilot study have been published in
extended abstract form (Sargent et al, 1999). As the major toxicity
of ara-C is associated with myelosuppression, we also investigated
the haematological toxicity of its combination with aphidicolin
using stem cell rich cord blood samples. 
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MATERIALS AND METHODS 
Patients and samples 
23 samples were received from 22 patients with AML; 19 with de
novo AML (13 on first presentation, 5 on relapse and 1 patient
tested twice – on presentation and relapse) and 3 with AML 2˚ to
MDS all of whom were chemotherapy naive. Approximately 5 ml
of bone marrow (10 samples) or 40 ml of peripheral blood (13
samples) were collected into citrate phosphate dextrose and tested
within 48 hours. Blast cells were harvested using density gradient
centrifugation (Histopaque, Sigma) and washed twice in RPMI
1640. A final cell suspension was prepared at approximately
1–2  ´ 106 blasts ml–1 RPMI 1640 plus 10% fetal calf serum (FCS),
100 IU ml–1 penicillin, 100 mg ml–1 streptomycin (all Sigma,
Poole, UK). Morphology was checked using May Grünwald
Giemsa stain on a cytospin of the final cell preparation. All
samples contained >80% blast cells. 
Drug exposure 
Blast cells were continuously exposed at 37˚C, 5% CO2 for
48 hours in 96-well microtitre plates to 4 concentrations of cyto-
toxic drugs commonly used to treat AML. Drugs tested included
the antimetabolites: ara-C, fludarabine (Flud); anthracyclines:
daunorubicin (DNR), doxorubicin (DOX); epipodophyllotoxin:
etoposide (Etop). Aphidicolin (Sigma, Poole, UK) was tested as a
single agent in 12 cases and did not appear to be cytotoxic up to a
concentration of 30 mM. Therefore, continuous exposure to cyto-
toxic agents took place in the presence or absence of a fixed
concentration of aphidicolin (15 mM) the concentration found to
inhibit DNA repair in our previous study (Sargent et al, 1996).
Control wells contained cells plus medium or, to control the co-
incubation experiments, medium plus aphidicolin at 15 mM. 
MTT assay 
The method used was similar to that previously described (Sargent
and Taylor, 1989). After 48 hours the drugs and medium were
removed from the wells by flicking and 50 ml of MTT solution 
(2 mg MTT ml–1 Hanks balanced salt solution without phenol red)
was added to all wells. The microtitre plates were re-incubated for
4 hours and any formazan crystals formed were dissolved in
acid/alcohol (0.04 N HCl in isopropanol). The plates were read at
570 nm (reference 690 nm) on an Anthos 2001 plate reader. 
The LC50 (drug concentration lethal for 50% of cells) was calcu-
lated or predicted using our own customized software for each
experiment. Patients were deemed sensitive if the LC50 value for
individual drugs fell below the cut off points given in Table 1,
resistant if above. These cut-off values have been previously
validated by correlation with the induction of remission (Sargent
and Taylor, 1989; Sargent et al, 1997) 
The fold difference in cytotoxicity on co-incubation with
aphidicolin was measured as the sensitization ratio: LC50 of drug
over LC50 in the presence of aphidicolin therefore, positive modu-
lation effects were indicated by a ratio >1.0. 
DNA analysis 
Apoptotic cells, analysed using flow cytometry, are clearly distin-
guishable as distinct subpopulations using DNA content and light
scatter measurements (Sherwood and Schimke, 1995). Cells were
exposed to ara-C ± aphidicolin for 48 hours then pelleted and fixed
by dropwise addition of 70% ice-cold ethanol while vortexing.
Controls consisted of blast cells incubated in medium or medium +
aphidicolin at 15 mM for 48 hours. Cells were then stored at 4˚C
for up to 1 month until required. After the addition of RNase
(1 mg ml–1; Sigma, Poole), cells were stained with propidium
iodide (PI; 400 mg ml–1 PBS; Sigma, Poole) for 30 min at 37˚C. A
Coulter Epics XL flow cytometer with an argon laser tuned to 488
nm was used to analyse the DNA content of the cells by measuring
forward and orthogonal light scatter and red fluorescence. A plot
of side scatter against PI staining was used to gate the sub G1
population of cells to give the percentage of cells with reduced
DNA content. When these cells were examined under a fluores-
cent microscope, they showed the typical signs of apoptosis with
chromatin condensation, cell shrinkage and blebbing of the
membrane. The percentage of remaining viable cells was calcu-
lated. 
Cord blood samples 
In order to establish the haematological toxicity of ara-C and
aphidicolin in combination, cells were obtained from cord blood
samples from 10 mothers, after informed consent. These cells
were prepared in the same way as the cells from AML patients,
then frozen in liquid nitrogen in RPMI 1640 with 20% FCS and
10% DMSO until required. After defrosting, the cells were washed
in medium to remove the DMSO then re-suspended at 1 ´ 106 ml–1
Table 1 Chemosensitivity and modulation by aphidicolin 
Drug LC50 median LC50 + aph median  Sensitization ratio median  Number SR>2/number  Cut-off for  Resistance rate
(range; mM) (range; mM) (range) tested resistance (%)
(mM)
ara-C 5.02 0.91* 4.75 16/23 2.5 15 (65) 
(0.25–41) (0.08–41) (0.8–80)
Flud 3.09 5.01 0.66 1/7 20 2 (29) 
(0.9–24) (1.5–70) (0.34–2.05)
DNR 0.8 0.53 1.38 1/11 1.0 1 (9) 
(0.07–3.9) (0.04–2.84) (0.71–4.15)
DOX 0.83 0.82 1.07 1/6 1.0 2 (33) 
(0.16–2.07) (0.02–2.07) (0.71–1.75)
Etop 44.2 41.5 1.11 0/13 25 10 (77) 
(4.25–93) (5.95–77) (0.71–1.75)
* P = < 0.005. 682 JM Sargent et al 
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in RPMI 1640 with 10% FCS and antibiotics. Cells were exposed
to ara-C ± aphidicolin as above. This was followed by the MTT
assay and the LC50 value was calculated for each sample. A CD34+
haematopoietic stem cell count was performed according to the
published guidelines (Barnett et al, 1999). The CD34-PE and
CD45-FITC antibodies (Beckman Coulter, UK) were used and the
samples read on a Coulter Epics flow cytometer using the
ISHAGE sequential gating strategy. 
Statistics 
Non-parametric methods were used throughout. Wilcoxon signed
rank test was used to assess the effect of aphidicolin, with paired
data. The Mann Whitney U test was used to assess differences
between groups of patients. The Spearman’s rank correlation coef-
ficient was used to compare drug LC50 values with sensitization
ratios. A P value of ≤ 0.05 was considered significant. 
RESULTS 
Drug sensitivity 
There was a marked variation in the effect of the antimetabolites
and etoposide between patients (Table 1). This variation was not so
pronounced for the anthracyclines, with a low overall resistance
rate in this group of patients. 
Modulation by aphidicolin 
Table 1 shows the median and range of LC50 values obtained for
each drug ± aphidicolin. The greatest effect overall was seen for
ara-C (P < 0.005). Up to 80-fold increases in sensitivity were
seen for 21 of the 23 samples tested, 16 (70%) having >2.0-fold
augmentation. Interestingly, aphidicolin had no significant effect
on the sensitivity of the other antimetabolite, fludarabine and had
minimal effect on the cytotoxicity of the anthracyclines or etopo-
side in this data set. There did not appear to be any correlation of
this effect with previous treatment or whether AML was the
primary disease or secondary to MDS. 
Relationship between sensitivity to ara-C and
modulation by aphidicolin 
There was a significant correlation between the LC50 values for
ara-C and the sensitization ratio calculated from co-incubation
with aphidicolin (rs = 0.453, n = 22, P < 0.05). Indeed, when
patients were grouped according to in vitro sensitivity to ara-C, the
modulation effect of aphidicolin was significantly greater for
blasts cells from the resistant group (median 8.9-fold increase in
sensitivity compared to 2.12-fold for the sensitive group, P < 0.01,
Figure 1). 
Correlation between DNA analysis and MTT assay 
Figure 2 shows the increase in the subdiploid population of blast
cells on co-incubation in ara-C + aphidicolin for 48 hours
compared to ara-C alone. There was a significant correlation
between the percentage of viable diploid cells as measured by flow
cytometry and the percentage cell survival as measured by the
MTT assay (Figure 3, n = 12, r = 0.869). These results validate the
use of flow cytometry to study chemosensitivity in these fresh
tumour samples since the same results were achieved as with the
MTT assay. The method is simple, reliable and cheap and has the
advantage of batching samples for analysis. 
Effect of ara-C ± aphidicolin on cord blood cells 
The cells from all but one of the cord blood samples appeared
resistant to ara-C with a median LC50 value of 8.75 mM (range
1.56–22.6) compared to 5.02 mM (range 0.25–41) for AML blast
cells. As with blast cells, sensitivity to ara-C was significantly
increased overall after co-incubation with aphidicolin (P < 0.02).
However, the median sensitization ratio was 3.7 which was not
significantly different from that of 2.12 obtained for blasts cells
which were sensitive to ara-C. When the therapeutic index of the
effect of ara-C on normal cells from cord blood over that for blast
cells was calculated (Table 2), the index for ara-C + aphidicolin
was higher than that for ara-C alone suggesting this combination
may be less myelotoxic than ara-C alone. The median CD34+ stem
cell percentage was 2.13% compared to the expected CD34+
population in peripheral blood of 0.01–0.05% (Barnett et al, 1999). 
DISCUSSION 
The low overall survival rate in adult AML is normally attributed
to the development of drug resistance. The MDR1 phenotype,
associated with resistance to the anthracyclines, is important in
this disease and numerous attempts have been made to overcome
this resistance with MDR modulators but with mixed results
(Covelli, 1999). Our results suggest it may be more pertinent to
modulate resistance to the commonly used antimetabolite, ara-C.
We have shown it is possible to markedly increase the in vitro
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Figure 1 The effect of aphidicolin according to blast cell sensitivity to ara-C.
The sensitization ratio (SR) represents the fold increase in sensitivity found
on co-incubation with 15 mM aphidicolin. The median SR (lines) for the
resistant group (n = 15) was significantly greater than for the sensitive group
(n = 8; P < 0.01) Aphidicolin increases sensitivity to ara-C in AML 683
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sensitivity to ara-C in these blast cells from clinical samples up to
80-fold using the DNA polymerase inhibitor, aphidicolin. 
These results agree with those we found previously, when
testing cells from patients with ovarian cancer against the platinum
agents in the presence of aphidicolin (Sargent et al, 1996). Here,
we found significant increases in sensitivity up to 60-fold. The
median increase was 10-fold which is comparable to that found
overall for the AML blast cells tested against ara-C (Table 1).
Furthermore, over 2-fold increases in sensitivity were seen for the
majority of cases in both these tumour types. In the present study,
there was only one instance of slightly reduced ara-C cytotoxicity
(sensitization ratio = 0.8). This patient appeared to have extreme
resistance to ara-C and our results suggest that this was mani-
fested by a mechanism of resistance other than increased DNA 
repair. 
Several studies have shown aphidicolin can increase sensitivity
to a variety of drugs, both in cell lines (Kuwakado et al, 1993;
Moreland et al, 1999) and in fresh cells obtained from patients
with chronic lymphocytic leukaemia (Bramson and Panasci,
1995). Nevertheless, there is one recent report using human lung
cancer cell lines where sensitivity to cisplatin was unaffected by
aphidicolin, possibly because a 1000-fold lower concentration was
used (Heim et al, 2000). We have found that 15 mM aphidicolin is
non-cytotoxic in vitro whilst being clinically achievable (Sessa 
et al, 1991). 
Table 2 Haematological toxicity of ara-C ± aphidicolin 
ara-C ara-C + aph 
Cord blood 8.75 1.92 
median LC50 (mM)
AML blasts 5.02 0.91 
median LC50 (mM)
Therapeutic index 1.74 2.1 
Normal cells/tumour cells
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DNA
0
(A)
(B)
(C)
(D)
1023
0 1023
E
v
e
n
t
s
0 1023
E
v
e
n
t
s
0 1023
E
v
e
n
t
s
E
v
e
n
t
s
0
128
0
256
0
0
512
0
1024
Figure 2 DNA analysis after 48 hour drug exposure in blast cells from a
patient with AML. Cells were fixed then stained with propidium iodide in the
presence of RNase. (A) culture medium; (B) 15 mM aphidicolin; (C) 5 mM
ara-C; (D) the increased effect of 5 mM ara-C + 15 mM aphidicolin is clearly
identified in the subdiploid population of cells 
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Figure 3 Relationship between cell survival as measured by the MTT assay
and by DNA analysis (n = 12, r = 0.869) 684 JM Sargent et al 
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Probably the most interesting and clinically relevant finding of
these studies is the increase in the modulation effect of aphidicolin
in the group of patients showing in vitro resistance to the drug
under test. This observation agrees with the theory that resistant
cells often have an increased capacity to repair damaged DNA and
suggests that the more resistant the patient to the drug in question
the better the effect of aphidicolin, thereby benefiting the patient
population most requiring rescue. The positive correlation
between ara-C LC50 values and the increase in sensitivity afforded
by aphidicolin agrees with our previous findings for the platinum
agents in ovarian cancer. In this earlier investigation, we found that
there was no correlation between the modulation effect of aphid-
colin and the number of tumour cells in the final cell population. 
It was interesting to see that a strikingly similar picture emerged
with the tumour cell rich samples in the present study (blast cells
>80% in all cases). We previously postulated that enhanced DNA
repair may be a feature of ‘resistant’ tumour cells rather than
‘resistant’ normal cells and the results obtained from testing cells
from cord blood support this hypothesis. 
Whilst aphidicolin increased sensitivity to ara-C in the cord
blood cells, the median fold-increase was lower than that found for
the blast cell population overall, 3.7-fold compared to 4.75-fold. If
this comparison is made with the blast cells found resistant to ara-
C in vitro (8.9-fold) then the difference becomes more apparent.
These data therefore suggest a good therapeutic index for this
combination. As only a small percentage of cells in the cord blood
samples were stem cells, our results could be misleading. Yet, no
difference in the metabolism of ara-C has been found between
CD34+ stem cells isolated by FACS and normal bone marrow
mononuclear cells (Braess et al, 1999). Because mononuclear cells
isolated from cord blood closely resemble the morphology of those
from normal bone marrow they can provide a good surrogate for
investigations of haematological toxicity (Ghielmini et al, 1997),
particularly as they are far easier to obtain. 
DNA damage repair can take many forms (Barret and Hill,
1998) usually ending with a re-synthesis step requiring DNA poly-
merase (pol). The repair mechanism most affected by inhibiting
these polymerases with aphidicolin remains the subject of conjec-
ture. Aphidicolin appears to inhibit pol-a, -d and -e therefore base
excision repair is an unlikely candidate, as pol-b has been
described as the major enzyme involved (Wood, 1996). A more
likely contender is nucleotide excision repair (NER) as both pol-d
and -e are known to be responsible for NER synthesis. It would be
interesting to investigate the expression of the proteins involved in
NER such as XPA and ERCC1/XPF in these fresh blast cells to
further elucidate the mechanism responsible for this effect.
Mismatch repair (MMR) is also possible, as resynthesis after the
mismatch is removed is thought to be carried out by pol-d
(Longley et al, 1997). However, this possibility is confounded by
the fact that aphidicolin appears to modulate resistance to cisplatin
in MMR defective cells (Moreland et al, 1999). 
Despite inhibitors of topoisomerase ll being associated with
DNA repair (McKenna and Padua, 1997), we did not see any
significant effect of aphidicolin on sensitivity to doxorubicin,
daunorubicin or etoposide. Because damage by these agents
involves changes in the topology of DNA, increasing cytotoxicity
by inhibiting DNA polymerases may not be as pertinent as it is for
antimetabolites and alkylating agents, which after incorporation
into DNA have to be removed and replaced to repair the damage.
Indeed, the involvement of doxorubicin in NER, for example, is
still a matter of debate (Barret and Hill, 1998). Also, it could be
that modulation of the anthracyclines was low in this study since
very few blast cells appeared to be resistant to these agents. It
would be interesting to test more samples from previously treated
patients on relapse. We are unable to explain the lack of efficacy
seen for combining fludarabine with aphidicolin. 
Both aphidicolin and ara-C have been described as DNA poly-
merase inhibitors so questioning the mode of action of this syner-
gistic effect. There is clear evidence to suggest that ara-C may
inhibit polymerases indirectly by termination of DNA chain elon-
gation. Once incorporated at the 3¢-end of DNA ara-CMP serves as
a poor substrate for the addition of a subsequent deoxynucleotide
(Plunkett and Ghandi, 1993). Aphidicolin, on the other hand,
directly competitively inhibits the enzymes themselves. As a
major mechanism of ara-C resistance is conferred by alterations in
the enzymes that influence the conversion of ara-C to ara-CTP, it is
possible that aphidicolin modulates the rate of intracellular accu-
mulation of ara-CTP. However, studies on proliferating human
fibroblasts suggest that this is not the case (Mirzayans et al, 1994).
Another mechanism of action for the synergy between ara-C and
aphidicolin has been postulated by Kuwakado et al (1995). They
found that aphidicolin significantly augmented ara-C-induced
c-jun upregulation and NF-kB activation in a human myeloid
leukaemia cell line. This correlated well with the potentiation by
aphidicolin of ara-C-induced apoptosis. As several investigators
have described the induction of transcription factors such as c-jun
and NF-kB as necessary for the apoptotic process, any increase
should lead to greater cell kill. Further mechanistic studies are
required to elucidate the biochemical or biological basis of the
observed modulation of ara-C sensitivity by aphidicolin. 
This is the first detailed report of the positive modulation effect
of aphidicolin on resistance to ara-C in fresh blast cells from
patients with AML. Resistance to ara-C has previously been
described as an indicator of reduced disease free survival in this
disease and we have found that blast cells from 50–60% of AML
patients appear to be resistant in vitro to this agent. Despite these
observations ara-C is included in most AML drug regimens, there-
fore attempts to overcome resistance to this agent become essen-
tial. Aphidicolin has already been through clinical trial with
minimum toxicity but it lacked significant antitumour activity as a
single agent. As has been the fate of other such compounds (Von
Hoff, 1998), this promising addition to the cytotoxic repertoire has
been shelved. Our study clearly demonstrates the remarkable
ability of aphidicolin to modulate resistance to ara-C. This, along-
side our increasing understanding of the importance of DNA repair
in failure of chemotherapy (Barret and Hill, 1998) make it the ideal
candidate for inclusion in future therapeutic programmes for
cancer chemotherapy. 
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